Carina Zötsch

Carina Zötsch

Auto-generated profile, based on publicly available information

Carina Zötsch

Clinical Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
UHUlrike Höckendorf
Ulrike Höckendorf
SDSayantanee Dutta
Sayantanee Dutta
AKArnold Kloos
Arnold Kloos
MRMarah Runtsch
Marah Runtsch
CZCarina Zötsch
Carina Zötsch
PJPhilipp J. Jost
Philipp J. Jost
Acute myeloid leukemia (AML) is characterized by frequent relapse, which is driven by resistant leukemic stem or progenitor cells (LSCs). Here, we reported on a tumor-suppressive mechanism that can be harnessed to simultaneously clear LSCs and promote healthy hematopoiesis. Genetic deletion of the tumor necrosis factor (TNF) superfamily member lymphotoxin alpha ( Lta ) blocked cell death and accelerated leukemogenesis in murine AML models. Accordingly, exposure of leukemic cells to exogenous recombinant lymphotoxin alpha (LTα 3 ) induced myeloid differentiation and, in part, cell death in AML progenitors. In syngeneic and patient-derived xenograft mouse models, exposure to recombinant LTα 3 resulted in deep and durable remissions. LTα 3 repressed leukemia by depleting tumor necrosis factor receptor (TNFR)–associated factor 2 (TRAF2) through activation of TNF receptors TNFR1 and TNFR2. In contrast with conventional therapies, LTα 3 exerted only minimal toxicity on the healthy hematopoiesis but instead promoted hematopoietic progenitors. Leveraging this endogenous tumor-suppressive mechanism may decouple treatment efficacy on malignant cells from undesired bone marrow suppression.